Proactive Investors - Run By Investors For Investors

Aequus Pharmaceuticals signs deal with world-renowned eye clinic to use Zepto system in cataract surgeries

Zepto will be used in one of the top clinics in Canada, where more than 10,000 cataract surgeries are performed every year
Zepto provides consistent, high quality anterior lens capsulotomies during cataract surgery in a cost-effective, disposable format

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCMKTS:AQSZF) announced Thursday that its cataract technology system, Zepto Capsulotomy, will be used at the world-renowned Kensington Eye Institute.

The Zepto Capsulotomy system provides consistent, high-quality anterior lens capsulotomies during cataract surgery in a cost-effective, disposable format.

Based in Toronto, the Kensington Eye Institute is a leader in Canada for cataract, glaucoma and retina surgery. Home to some of the top eye surgeons in the country, Kensington pioneers the introduction and development of new ophthalmology technologies.

READ: Aequus Pharmaceuticals brings in $2.35 million after closing offering

“The Zepto Capsulotomy System has received positive feedback with our customers in specific types of cataract surgeries,” said Ian Ball, CCO of Aequus.

“We’re proud to have the Zepto placed in one of the top clinics in Canada, where over 10,000 cataract surgeries are performed every year. This placement, along with the extension of the distribution agreement, provides further validation of Aequus’ ability to successfully commercialize assets within Canada.”

Aequus also announced it had extended its agreement with Mynosys Cellular Devices Inc to distribute Zepto in Canada to April 2022.

The company said the supplier relationship "does not imply any endorsement of the product nor imply a broader strategic relationship" between the parties.

Based in Vancouver, Aequus has several commercial products in ophthalmology and transplant in its pipeline and a development stage pipeline in neurology and psychiatry. Its most recent addition to the pipeline was a long-acting form of medical cannabis.

—(Updates with disclaimer)—

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full AQS profile View Profile

Aequus Pharmaceuticals Inc Timeline

Related Articles

cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use